Biogen has acquired an exclusive option to TMS’ Phase II acute stroke candidate TMS-007 and backup compounds through a deal that could generate up to $357 million-plus for the Japanese biotech and is ...
Use of inhibitory transcranial magnetic stimulation (TMS) over the speech area in the right side of the brain significantly improved language recovery in patients with stroke, new research shows. "The ...
According to the CDC, each year more than 795,000 people in the US have a stroke, of which 610,000 first-time strokes. About 140,000 Americans die from stroke each year — about 1 out of every 20 ...
Biogen signed a deal for an exclusive chance to acquire TMS’ treatment for restoring blood flow after acute ischemic stroke, which is currently being evaluated in a placebo-controlled phase 2 study in ...
TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current ...
In a recent study, researchers from Xi'an Jiaotong-Liverpool University and other universities in China have reported that brain stimulation combined with a nose spray containing nanoparticles can ...
MAYWOOD, IL. - Transcranial magnetic stimulation (TMS) has shown significant efficacy in treating major depressive and obsessive compulsive disorders. A newly published literature review by Antonio H.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results